Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 17.72 -0.75 (-4.06%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA October 14, 2022 Via Benzinga Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy October 13, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market October 05, 2022 Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. Via InvestorPlace Travere Therapeutics Return On Capital Employed Overview August 15, 2022 Via Benzinga Recap: Travere Therapeutics Q2 Earnings August 04, 2022 Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement. Via Benzinga 121 Stocks That Hit Their 52-Week Low October 14, 2022 New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. Via Benzinga Expert Ratings for Travere Therapeutics October 14, 2022 Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: Via Benzinga FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease October 14, 2022 Via Benzinga Recap Of Monday's Biotech Catalysts - End Of the Day Summary August 22, 2022 Via Benzinga Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder August 22, 2022 Via Benzinga Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate August 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication August 04, 2022 Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare... Via Benzinga Where Travere Therapeutics Stands With Analysts July 26, 2022 Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter: Via Benzinga Analyst Ratings for Travere Therapeutics May 17, 2022 Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: Via Benzinga Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug May 16, 2022 The FDA will review Travere's drug by mid-November for a kidney disease. Via Investor's Business Daily 12 Health Care Stocks Moving In Wednesday's After-Market Session August 03, 2022 Gainers Via Benzinga 4 Analysts Have This to Say About Travere Therapeutics July 26, 2022 Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session June 17, 2022 Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion. Via Benzinga HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know May 17, 2022 HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%... Via Benzinga FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review May 16, 2022 The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of... Via Benzinga Here's Why Travere Therapeutics Shares Are Rising Today May 16, 2022 Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy... Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session May 06, 2022 Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. Via Benzinga Earnings Outlook For Retrophin May 04, 2022 Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will... Via Benzinga The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More May 02, 2022 Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... Via Benzinga The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data April 21, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More April 10, 2022 Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. Via Benzinga The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout March 08, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 March 31, 2022 Upgrades Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022 February 28, 2022 Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... Via Benzinga < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
